Summary
Dose-limiting toxicity secondary to antineoplastic chemotherapy is principally due to the inability of the drugs to differentiate between normal and malignant cells. This results in normal tissue damage, as well as the desired antitumour effect. Toxicity may be acute, as in cisplatin-induced nephrotoxicity or alkylating agent myelotoxicity and haemorrhagic cystitis, or cumulative, as in anthracyclinerelated cardiac toxicity or cisplatin neurotoxicity. The consequences of this often include serious adverse effects and the inability to deliver adequate dose-intensive therapy against the cancer.
Chemoprotective agents have been developed to provide site-specific protection against normal tissue toxicity, without compromising antitumour activity. Several chemoprotective compounds have recently been developed, including dexrazoxane (ICRF-187), amifostine (ethiofos; WR-2721), mesna and ORG-2766. Initial results confirm their promise as selective protective agents, although further randomised trials are required to identify their optimal role when used alone or in combination with other toxicity modifiers, including haematopoietic growth factors, with the ultimate aim being adequate dose escalation of chemotherapy to overcome tumour resistance.
Similar content being viewed by others
References
Handa K, Sato S. Generation of free radicals of quinone group containing anti-cancer chemicals in NADPH-microsome system as evidenced by initiation of sulfite oxidation. Jpn J Cancer Res 1975; 66: 43–75
Pigram WJ, Fuller W, Amilton LDH. Stereochemistry of intercalation: interaction of daunomycin with DNA. Nature 1972; 235: 17–9
Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710–7
Davies KJ, Doroshow JH. Redox cycling of anthracyclines by cardiac mitochondria I: antracycline radical formation by NADPH dehydrogenase. J Biol Chem 1986; 261: 3060–7
Bachur NR, Gordon SL, Gee MV. A general mechanism for microsomal activation of quinone anti-cancer agents to free radicals. Cancer Res 1978; 38: 1745–50
Thayer WS. Adriamycin stimulated superoxide formulation in submitochondrial particles. Chem Biol Interact 1977; 19: 265–78
Combs AB, Acosta D. Toxic mechanisms of the heart: a review. Toxicol Pathol 1990; 18: 593–6
Doroshow JH, Locker GY, Baldinger J, et al. The effect of doxorubicin on hepatic and cardiac glutathione. Res Commun Chem Pathol Pharmacol 1979; 26: 285–95
Legha S, Wang YM, Mackay B, et al. Clinical and pharmacological investigation of the effects of alpha-tocopherol on adriamycin cardiotoxicity. Ann NY Acad Sci 1982; 393: 411–8
Myers CE, Bonow R, Palmeri S, et al. A randomised controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol 1983; 10 Suppl. 1: 53–5
Myers CE, Gianna L, Zweier J, et al. The role of iron in adriamycin biochemistry. Fed Proc 1986; 45: 2792–7
Sugioka KA, Nakano M. Mechanisms of phospholipid peroxidation induced by ferric iron-ADP adriamycin co-ordination complex. Biochem Biophys Acta 1982; 713: 333–43
Herman EH, Mhatre R, Chadwick D. Modification of some of the toxic effects of daunomycin (NSC-82151) by pretreatment with anti-neoplastic agent ICRF-159 (NSC-129943). Toxicol Appl Pharmacol 1974; 27: 517–26
Herman EH, Witiak DT, Hellman K, et al. Biological properties of ICRF-159 and related bisdioxopiperazine compounds. Adv Pharmacol Chemother 1985; 19: 249–301
Speyer JL, Green MD, Kramer E, et al. Protective effects of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988; 319: 745–52
Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992; 10: 117–27
ten Bokkel-Huinink WW, Schreuder JE, Dubbleman R, et al. ICRF-187 protects against doxorubicin induced cardiomyopathy [abstract]. Ann Oncol 1992; 3 Suppl. 1: A221
Weisberg SR, Rosenfeld CS, York RM, et al. Dexrazoxane (ADR-529, ICRF-187, Zinecard) protects against doxorubicin induced chronic cardiotoxicity. Proc Am Soc Clin Oncol 1992; 11: 190
Feldman JE, Jones SE, Weisberg SR, et al. Advanced small cell lung cancer treated with CAV chemotherapy and cardioprotective agent dexrazoxane (ADR-529, ICRF-187, Zinecard). Proc Am Soc Clin Oncol 1992; 11: 993
Liesmann J, Belt R, Haas C, et al. Phase I evaluation of ICRF-187 (NSC-169780) in patients with advanced malignancy. Cancer 1981; 47: 1959–62
Coleman N, Bump E, Kramer R. Chemical modifiers of cancer treatment. J Clin Oncol 1988; 6: 709–33
Spencer CM, Goa KL. Amifostine: a review of its pharmacodynamic and phamocokinetic properties, and therapeutic potential as a radioprotective and cytotoxic chemoprotector. Drugs. In press
Schuchter LM, Luginbuhl WE, Meropol NJ. The current status of toxicity protectants in cancer therapy. Semin Oncol 1992; 19: 742–51
Calabro-Jones P, Aguilera JA, Ward JF, et al. Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Res 1988; 48: 3634–40
Smoluk GD, Fahey RC, Calabro-Jones PM, et al. Radioprotection of cells in culture by WR-2721 and derivatives: form of the drug responsible for protection. Cancer Res 1988; 48: 3614–7
Yuhas JM. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminoprophylamino)-ethylphosphorothioic acid. Cancer Res 1980; 40: 1519–24
Tahsildar HI, Biaglow JE, Kligerman MM, et al. Factors influencing the oxidation of the radioprotector WR-1065. Radiat Res 1988; 113: 243–51
Shaw L, Glover D, Turrisi A, et al. Pharmocokinetics of WR-2721. Pharmacol Ther 1988; 39: 195–201
Glover D, Glick J, Weiler C, et al. Phase I trials of WR-2721 and cisplatinum. Int J Radiat Oncol Biol Phys 1984; 10: 1781–4
Kligerman M, Glover D, Turrisi A, et al. Toxicity of WR-2721 administered in single and multiple doses. Int J Radiat Oncol Biol Phys 1984; 10: 1773–6
Turrisi AT, Glover DJ, Hurwitz S, et al. Final report of the phase I trial of single dose WR-2721 S-2-(3-aminoprophylamino)-ethylphosphorothioic acid. Cancer Treat Rep 1986; 70: 1389–93
Glover D, Riley L, Carmichael K, et al. Hypocalcemia and inhibition of parathyroid hormone secretion after administration of WR-2721 (a radioprotective and chemoprotective agent). N Engl J Med 1983; 309: 1117–41
Walder S, Haynes H, Butler JJ, et al. Management of hypocalcemic effects of WR-2721 administered on a daily times five schedule with cisplatin and radiation therapy. J Clin Oncol 1993; 11: 1517–22
Glover D, Grabelsky S, Fox K, et al. Clinical trial of WR-2721 and cisplatinum. Int J Radiat Oncol Biol Phys 1989; 16: 1201–4
Mollman JE, Glover DJ, Hogan WM, et al. Cisplatin neuropathy: risk factors, prognosis and protection by WR-2721. Cancer 1988; 61: 2192–5
Glick JH, Glover DJ, Weiler C, et al. Phase I controlled trials of WR-2721 and cyclophosphamide. Int J Radiat Oncol Biol Phys 1984; 10: 1777–80
Glover D, Glick JH, Weiler C, et al. WR-2721 protects against the haematologic toxicity of cyclophosphamide: a controlled phase II trial. J Clin Oncol 1986; 4: 584–8
Woolley PV, Ayoob MJ, Smith FP, et al. Clinical trial of S-2-(3-aminoprophylamino)-ethylphosphorothioic acid (WR-2721) (NSC 296961) on the toxicity of cyclophosphamide. J Clin Oncol 1983; 1: 198–203
Glick J, Kemp G, Rose P, et al. A randomised trial of cyclophosphamide and cisplatin ± WR-2721 in the treatment of advanced epithelial ovarian cancer. Proc Am Soc Clin Oncol 1992; 11: 258
Luginbuhl W, Tester W, Shaw L, et al. One or two doses of WR-2721: does it protect patients receiving carboplatin? Proc Am Soc Clin Oncol 1992; 11: 312
Browne MJ, Clark JW, Weitberg A, et al. A phase I-II study of WR-2721 and carboplatin in patients with advanced lung and breast cancer. Proc Am Soc Clin Oncol 1993; 12: 452
Cox PJ. Cyclophosphamide cystitis: identification of acrolein as the causative agent. Biochem Pharmocol 1979; 28: 2045–9
Brock N, Pohl J, Stekar J, et al. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention — III: profile of action of sodium 2-mercaptoethane sulfonate (Mesna). Eur J Cancer Clin Oncol 1982; 18: 1377–87
Scheef W, Klein HO, Brock N, et al. Controlled clinical studies with an antidote against the urotoxicity of oxaza-phosphorines: preliminary results. Cancer Treat Rep 1979; 63: 501–5
Fukuoka M, Negoro S, Masuda N, et al. Placebo-controlled double blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders. J Cancer Res Clin Oncol 1991; 117: 473–8
Munshi NC, Loehrer Sr PJ, Williams SD, et al. Comparison of N-acetylcysteine and mesna as uroprotectors with ifosfamide combination chemotherapy in refractory germ cell tumours. Invest New Drugs 1992; 10: 159–63
Legha S, Papadopoulos N, Plager C, et al. A comparative evaluation of the uroprotective effect of mercaptoethane sulfonate (mesna) and N-acetylcysteine (NAC) in sarcoma patients treated with ifosfamide. Proc Am Soc Clin Oncol 1990; 9: 1205
Blomgren H, Hallstrom M, Hillgren H. Antitumour activity of 2-mercaptoethane sulfonate (mesna) in vitro: its potential use in the treatment of superficial bladder cancer. Anticancer Res 1991; 11: 773–6
Burkert H. Clinical overview of mesna. Cancer Treat Rev 1983; 10: 175–81
Pohl VJ, Brock N, Schneider B, et al. Zur Pharmakokinetik von uromitexan. Methods Find Exp Clin Pharmacol 1981; 3 Suppl. 1: 95–101
Burkert H, Lucker W, Wetzelsberger N, et al. Bioavailability of orally administered mesna. Arzneimittelformschung 1984; 34: 1597–600
Goodman TL, McKenna LM, Li JT, et al. Clinical pharmacology and efficacy of mesna given po to outpatients treated with ifosfamide for solid tumours. Proc Am Soc Clin Oncol 1992; 11: 272
Katz S, Epelman S, Annelli A, et al. Mesna (M) — based uroprotection: sustained and simplified schedule — results of a randomised trial. Proc Am Soc Clin Oncol 1992; 11: 1351
Dorr RT. Chemoprotectants for cancer chemotherapy. Semin Oncol 1991; 18 Suppl. 2: 48–58
Radford JA, Margison JM, Swindell R, et al. The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump. J Cancer Res Clin Oncol 1991; 117 Suppl. 4: 154–6
Cerny T, Graf A, Rohner P, et al. Subcutaneous continuous infusion of ifosfamide and cyclophosphamide in ambulatory cancer patients: bioavailability and feasibility. J Cancer Res Clin Oncol 1991; 117 Suppl. 4: 129–34
Reinhold-Keller E, Mohr J, Christophers E, et al. Mesna side-effects which imitate vasculitis. Clin Investig 1992; 70: 698–704
Hamers FPT, Gispen WH, Neijt JP. Neurotoxic side-effects of cisplatin. Eur J Cancer 1991; 27: 372–6
Strand FL, Kung TT. ACTH accelerates recovery of neuromuscular function following crushing of peripheral nerve. Peptides 1980; 1: 135–8
Gerritsen Van der Hoop R, de Koning P, Boven E, et al. Efficacy of the neuropeptide ORG-2766 in the prevention and treatment of cisplatin-induced neurotoxicity in rats. Eur J Cancer Clin Oncol 1988; 24: 637–42
Gerritsen Van der Hoop R, Vecht CJ, van der Burg MEL, et al. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med 1990; 322: 89–94
Hovestadt A, van der Burg ME, Verbiest HB, et al. The course of neuropathy after cessation of cisplatin treatment combined with ORG-2766 or placebo. J Neurol 1992; 239: 143–6
van der Burg ME, Verbiest HB, van Putten WL, et al. Phase II study to assess the effect of ORG-2766 on the recovery of late cisplatin-induced neuropathy. Proc Am Soc Clin Oncol 1992; 33: 1542
Hamers FP, Pette C, Neijt JP, et al. The ACTH-(4-9) analog ORG-2766 prevents taxol-induced neuropathy in rats. Eur J Pharmacol 1993; 233: 177–8
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lewis, C. A Review of the Use of Chemoprotectants in Cancer Chemotherapy. Drug-Safety 11, 153–162 (1994). https://doi.org/10.2165/00002018-199411030-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199411030-00002